*All times show in EDT

9:30 am Virtual Coffee & Networking

9:55 am Chair’s Welcome

Bioinformatic Platforms to Identify Optimal Infectious Disease Targets

10:00 am Bioinformatics to Discover Novel T Cell Targets in COVID-19


  • Outline the T-Scan target discovery platform to identify the precise epitope targets in the novel coronavirus that are recognized by the T-cells of convalescent patients
  • Review immunogenicity data to identify which epitopes are crucial to prevent COVID-reinfection and aid vaccine development
  • Outline HLA matching considerations and limitations when identifying T-cells targets

10:30 am Adoptive Cellular Immunotherapy for Virus-Associated Diseases

  • Rajiv Khanna Professor, Senior Scientist & Deputy Coordinator of Immunology Department , QIMR Berghofer


  • Adoptive T-cell therapy as first-line treatment of viral infections in transplant recipients
  • Outline how molecular signatures of T-cell drug products can impact clinical response
  • Describe how off-the-shelf T-cell therapies offer rapid and safe therapeutic strategy for viral infections

11:00 am Morning Refreshments & Virtual Networking

Preclinical Models to Confidently Make Translatable Predictions

12:00 pm Preclinical Studies for COVID-19 Vaccine Development

  • Drew Weissman Professor of Medicine , University of Pennsylvania


  • Discuss best-in-class preclinical models for COVID-19 and potential short falls
  • Share pre-clinical data regarding T-cell expansion and durability

12:30 pm Group Discussion Session:


Join the conversation to engage with this community in thought-provoking discussion sessions.

A) Identifying Future Infectious Disease Targets
Which chronic infectious disease would benefit from T-cell mediated therapy?

B) Regulatory Considerations for Infectious Disease Trials
Address the difficulty with bridging the gap between preclinic and clinical translation in a new research area where regulatory guidelines are ever changing

1:30 pm Lunchtime Refreshments

Compare Vaccine Design and Delivery for COVID-19 to Determine which Technology is Best Able to Generate a Durable, Potent T-Cell Attack

2:30 pm A 2nd Generation Vaccine to Drive Strong Neutralizing Antibody and CD8 T-cell Responses against SARS-CoV-2

  • Roman Yelensky Executive Vice President & Chief Technology Officer , Gritstone Oncology


  • Mutations in Spike may reduce protection from first generation vaccines
  • Gritstone’s vaccine platform combines two potent vectors to elicit strong antibody and CD8 T cell responses
  • Targets from multiple viral genes are added to maximize CD8 T-cell response breadth and enhance protection

3:00 pm Using an Inflammatory Chemokine Linked to the Antigen Generates a Rapid, Strong and Broad Immune Response


  • Describe rapid onset after a single dose
  • Th1 and CD8 T-cell dominated responses
  • Long-lasting and strong memory T-cell responses

3:30 pm T Cell-Directed COVID-19 Peptide Vaccine Development Using Immunoinformatics

  • Lenny Moise Director, Vaccine Research , EpiVax, Inc.


  • Describe the role of T cell immunity in COVID-19 and the current vaccine landscape
  • Discuss immunoinformatic discovery and validation of SARS-CoV-2 T cell epitopes and preclinical vaccine data
  • Outline plan for phase 1 clinical trial

4:00 pm Closing Remarks & Close of Summit